ProCE Banner Activity

BELLINI Phase II Trial: Nivolumab + Ipilimumab in Patients With Early-Stage TNBC With Tumor-Infiltrating Lymphocytes

Slideset Download
Conference Coverage
First results from the BELLINI trial evaluating the combination of nivolumab + ipilimumab before the start of neoadjuvant chemotherapy or surgery show promise in early TNBC with TILs.

Released: September 12, 2022

Expiration: September 11, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.